Indazoles as potential c-met inhibitors: Design, synthesis and molecular docking studies

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 112-118

  Ye, Lianbao ^a   Ou, Xiaomin ^a   Tian, Yuanxin ^b   Yu, Bangwei ^a   Luo, Yan ^a   Feng, Binghong ^a   Lin, Hansen ^a   Zhang, Jiajie ^b   Wu, Shuguang ^b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bioisosterism principles; c Met inhibitor; Indazole; Isomer; Molecular docking; Suzuki coupling reaction

Indexed keywords

1 (QUINOLIN 6 YLMETHYL) 6 (1 METHYL PYRAZOL 3 YL) 1H INDAZOLE; 1 (QUINOLIN 6 YLMETHYL) 6 [1 (2 HYDROXYETHYL) 1H PYRAZOL 4 YL] 1H INDAZOLE; 1 (QUINOLIN 6 YLMETHYL) 6 [1 (2 TETRAHYDRO 2H PYRAN 2 YLXYETHYL) 1H PYRAZOL 4 YL] 1H INDAZOLE; 1 (QUINOLIN 6 YLMETHYL) 6 [1 (4 HYDROXY CYCLOHEXYL) 1H PYRAZOL 4 YL] 1H INDAZOLE; 1 (QUINOLIN 6 YLMETHYL) 6 [1 [4 (TERT BUTYLDIMETHYLSILYLOXY)CYCLOHEXYL] 1H PYRAZOL 4 YL] 1H INDAZOLE; 2 (QUINOLIN 6 YLMETHYL) 6 (1 METHYL PYRAZOL 3 YL) 1H INDAZOLE; 2 (QUINOLIN 6 YLMETHYL) 6 [1 (2 HYDROXYETHYL) 1H PYRAZOL 4 YL] 1H INDAZOLE; 2 (QUINOLIN 6 YLMETHYL) 6 [1 (2 TETRAHYDRO 2H PYRAN 2 YLXYETHYL) 1H PYRAZOL 4 YL] 1H INDAZOLE; 2 (QUINOLIN 6 YLMETHYL) 6 [1 (4 HYDROXY CYCLOHEXYL) 1H PYRAZOL 4 YL] 1H INDAZOLE; 2 (QUINOLIN 6 YLMETHYL) 6 [1 [4 (TERT BUTYLDIMETHYLSILYLOXY)CYCLOHEXYL] 1H PYRAZOL 4 YL] 1H INDAZOLE; INDAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; MOLECULAR DOCKING;

EID: 84878009785     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.004     Document Type: Article

References (17)

1. K.H. Jung, B.H. Park, S.S. Hong, Progress in cancer therapy targeting c-Met signaling pathway, Arch. Pharm. Res. 4 (2012) 595-604.
2. E. Gherardi, W. Birchmeier, C. Birchmeier, G. Vande Woude, Targeting MET in cancer: rationale and progress, Nat. Rev. Cancer 2 (2012) 89-103.
3. S.G. Buchanan, J. Hendle, P.S. Lee, C.R. Smith, P.Y. Bounaud, SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo, Mol. Cancer Ther. 8 (2009) 3181-3190.
4. S.L. Timofeevski, M.A. McTigue, K. Ryan, J. Cui, H.Y. Zou, Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors, Biochemistry 48 (2009) 5339-5349.
5. G.M. Schroeder, G.M. Schroeder, Y. An, Z.W. Cai, Discovery of N -(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4- fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily, J. Med. Chem. 52 (2009) 1251-1254.
6. N.D. D'Angelo, S.F. Bellon, S.K. Booker, Y. Cheng, Design, synthesis, and biological evaluation of potent c-Met inhibitors, J. Med. Chem. 51 (2008) 5766-5779.
7. F. Chen, Y. Wang, J. Ai, Z.S. Zhan, Y.C. Lv, Z.J. Liang, C. Luo, D.S. Mei, M.Y. Geng, W.H. Duan, O-linked triazolotriazines: potent and selective c-Met, inhibitors, ChemMedChem 7 (2012) 1276-1285.
8. N. Munshi, S. Jeay, Y. Li, C.R. Chen, ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity, Mol. Cancer Ther. 9 (2010) 1544-1553, http://dx.doi.org/10.1158/1535-7163.MCT- 09-1173.
9. S. Eathiraj, R. Palma, E. Volckova, M. Hirschi, Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197, J. Biol. Chem. 286 (2011) 20666-20676.
10. J. Porter, Small molecule c-Met kinase inhibitors: a review of recent patents, Expert Opin. Ther. Pat. 20 (2010) 159-176.
11. H.M. Chen, J.R. Cui, J.E. Hoffman, M.C. Johnson, R.S. Kania, T.Q. Le, M.D. Nambu, M.A. Pairish, H. Shen, M.B. Tran-dube, PCT Int. Appl. WO 2007-132308, 2007.
12. T.B. Lu, R. Alexander, R.W. Connors, M.D. Cummings, R.A. Galemmo, H.R. Hufnagel, D.L. Johnson, E. Khalil, K.A. Leonard, T.P. Markotan, A.C. Maroney, J.L. Sechler, PCT Int. Appl. WO 075567, 2007.
13. L.B. Ye, Y.X. Tian, Z.H. Li, H. Jin, Z.G. Zhu, S.H. Wan, J.Y. Zhang, P.J. Yu, J.J. Zhang, S.G. Wu, Synthesis and molecular docking studies of some novel spiro[indoline-3,4′-piperidine]-2(1H)-ones as potential c-Met inhibitors, Eur. J. Med. Chem. 50 (2012) 370-375.
14. L.B. Ye, Y.X. Tian, Z.H. Li, J.J. Zhang, S.G. Wu, Design and synthesis of some novel 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles as potential c-Met inhibitors, Helv. Chim. Acta 95 (2012) 320-326.
15. K.L. Billingsle, S.L. Buchwald, an improved system for the palladium-catalyzed borylation of aryl halides with pinacol borane, J. Org. Chem. 14 (2008) 5589-5591.
16. A.N. Jain, Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine, J. Med. Chem. 46 (2003) 499-511. (Pubitemid 36182752)
17. A.N. Jain, Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search, J. Comput. Aided Mol. Des. 21 (2007) 281-306. (Pubitemid 46630055)